Extracellular matrix at sites of vascular injury (ECM)

The extracellular matrix (ECM) at sites of vascular injury refers to the complex network of proteins and glycosaminoglycans, such as collagen, von Willebrand factor (VWF), fibronectin, and laminin, that become exposed to flowing blood when the endothelial lining of a vessel is damaged. This exposed matrix serves as a critical prothrombotic substrate, initiating the hemostatic process by providing binding sites for platelet receptors like Glycoprotein VI and integrin α2β1, as well as adapter molecules like VWF. In pathological conditions such as atherosclerosis, the rupture of a plaque exposes this ECM, leading to rapid platelet aggregation and the formation of an occlusive thrombus, which can cause myocardial infarction or stroke. Therapeutic strategies targeting this environment include drugs that block platelet-ECM interactions, such as Revacept, or use the exposed matrix as a docking site for the localized delivery of anti-inflammatory or regenerative agents. Consequently, the ECM at injury sites is a pivotal target for managing cardiovascular diseases and preventing thrombotic complications. By specifically targeting the components of the injured matrix, researchers aim to develop therapies that provide localized treatment while minimizing systemic side effects like bleeding.

Other names

Subendothelial matrixExposed extracellular matrixVascular ECMSubendothelial extracellular matrix

Competitive inhibition of platelet-matrix interactions and site-specific delivery of therapeutic agents.